Ibudilast (MN-166

Drug Name: Ibudilast (MN-166
Company: MediciNova
Location: US-California
Website: http://www.medicinova.com
Drug Type: Small Molecule
Conditions: ALS, multiple sclerosis, neuropathic pain, addiction
Mechanism Type: Immunomodulation
Mechanism: Ibudilast is an orally bioavailable, centrally acting phosphodiesterase inhibitor that attenuates glial cell activation, at least in part, by reducing the effect of proinflammatory factors. MN-166 may minimize the production of pro-inflammatory cytokines.
U.S. Status for ALS: Phase II

[1] Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) (IBU-ALS-1201). ClinicalTrials.gov, 23 Sep 2015. Accessed 9 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT02238626.
[2] FDA Approves a New Clinical Protocol to Evaluate the Effects of MN-166 (ibudilast) on a Biomarker of ALS; MediciNova Plans to Initiate a Clinical Trial with MGH (Massachusetts General Hospital). MarketWatch, 9 Nov 2015. Accessed 9 Mar 2016 from http://www.marketwatch.com/story/fda-approves-a-new-clinical-protocol-to-evaluate-the-effects-of-mn-166-ibudilast-on-a-biomarker-of-als-medicinova-plans-to-initiate-a-clinical-trial-with-mgh-massachusetts-general-hospital-2015-11-09.

Last updated February 8th, 2018

Share this: